R&D channel feed

Pfiz­er’s once-a-week he­mo­phil­ia an­ti­body re­duces bleed­ing in PhI­II study

Last year

Af­ter PhI­II let­down, Rain On­col­o­gy lays off 65% of staff, al­ters clin­i­cal plans for sole as­set

Last year
People

EU com­mit­tee like­ly to rec­om­mend against ap­prov­ing Amy­lyx ALS drug, com­pa­ny says

Last year
Pharma
FDA+

Ve­rastem touts mid-stage da­ta in rare type of ovar­i­an can­cer: #AS­CO23

Last year

With cash run­ning low, Swedish cell ther­a­py com­pa­ny looks to sell off plat­form

Last year
Cell/Gene Tx

Evax­ion teas­es 67% re­sponse rate in PhI metasta­t­ic melanoma tri­al

Last year

Take­da wins pri­or­i­ty re­view for $400M col­orec­tal can­cer drug, li­censed from Hutchmed in Jan­u­ary

Last year
FDA+

Arti­va boasts ear­ly NK cell ther­a­py re­sults, giv­ing life­line to part­ner Af­fimed

Last year

Out­pace Bio ex­pands cell ther­a­py R&D, nets re­search col­lab­o­ra­tions in Seat­tle

Last year
Cell/Gene Tx

As­traZeneca's Lyn­parza-Imfinzi com­bo hits pri­ma­ry end­point in PhI­II en­dome­tri­al can­cer tri­al DUO-E

Last year

Car­mot rais­es an­oth­er $150M for obe­si­ty drugs, though race by com­peti­tors is well un­der­way

Last year
Financing
Startups

Bris­tol My­ers de­tails PhI­II win in first-line test of Re­blozyl for re­duc­ing trans­fu­sions in ear­ly blood can­cer pa­tients

Last year

BioX­cel looks to ex­pand la­bel to at-home use for lead psych drug. Ini­tial da­ta are mixed

Last year

Lil­ly gears up trio of PhI­II tri­als for its oral GLP-1 amid No­vo Nordisk, Pfiz­er com­pe­ti­tion

Last year
Pharma

Apel­lis re­ports PhII ALS fail af­ter stop­ping open-la­bel ex­ten­sion in April

Last year

Mi­rati’s drug sitra­va­tinib flops PhI­II in com­bo with Op­di­vo for cer­tain lung can­cer

Last year
Pharma

An­nex­on’s GA drug miss­es on pri­ma­ry goal but win on vi­su­al acu­ity will be fo­cus of planned late-stage tri­al

Last year
Pharma

Eloxx aims to take lead can­di­date in­to PhI­II for rare dis­ease

Last year

FDA de­lays Sarep­ta's Duchenne gene ther­a­py de­ci­sion by a month

Last year
Cell/Gene Tx

En­ta­sis lands first an­tibi­ot­ic ap­proval eight years af­ter spin­ning out of As­traZeneca

Last year

Phath­om Phar­ma­ceu­ti­cals re­sub­mits NDA for acid block­er, bags $130M+ from of­fer­ing

Last year
Financing

PTC cuts gene ther­a­py pro­grams, dis­clos­es PhI­II fail in Friedre­ich's atax­ia and CFO ex­it

Last year
Cell/Gene Tx

Weight loss field ex­pands as Pfiz­er's oral GLP-1 gath­ers com­par­isons to Novo's We­govy in PhII da­ta

Last year
Pharma

Af­fimed lays off around 50 staffers as it brings com­bo NK cell ther­a­py to PhII

Last year
People
First page Previous page 82838485868788 Next page Last page
A service from the Financial Times